सानोफी कंझ्युमर हेल्थकेअर इंडिया शेअरची किंमत

Dividend stocks: Among the companies, Sanofi Consumer Healthcare India has announced the highest final dividend of 75 per share, with June 19, 2026, fixed as the record date

• बिझनेस स्टँडर्ड
• 4 तास 17 मिनिटांपूर्वी

सनोफीच्या एआय-संचालित ॲक्सिलरेअर प्लॅटफॉर्मचे उद्दीष्ट डॉक्टरांना दुर्मिळ आजार वेगाने ओळखण्यास आणि भारतातील विशेषज्ञ उपचार केंद्रांना रेफरल सुधारण्यास मदत करणे आहे

• बिझनेस स्टँडर्ड
• 2 आठवडे 1 दिवसापूर्वी

Pharmaceuticals company Sanofi Consumer Healthcare India announced Q1CY26 & CY25 results Q1CY26 Financial Highlights: Revenue from Operations: Rs 2,292 million in Q1CY26, down 8.69% QoQ from Rs 2,510 million in Q4CY25, but up 32.79% YoY from Rs 1,726 million in Q1CY25. Total Income: Rs 2,348 million in Q1CY26, down 8.14% QoQ from Rs 2,556 million in Q4CY25, but up 32.06% YoY from Rs 1,778 million in Q1CY25. Profit Before Tax (PBT): Rs 907 million in Q1CY26, up 0.22% QoQ from Rs 905 million in Q4CY25 and up 35.78% YoY from Rs 668 million in Q1CY25. Net Profit for the Period: Rs 678 million in Q1CY26, up 1.95% QoQ from Rs 665 million in Q4CY25 and up 35.60% YoY from Rs 500 million in Q1CY25. Total Comprehensive Income: Rs 678 million in Q1CY26, compared to Rs 651 million in Q4CY25 (up 4.15% QoQ) and Rs 500 million in Q1CY25 (up 35.60% YoY). Earnings Per Share (EPS): Rs 29.44 in Q1CY26, compared to Rs 28.87 in Q4CY25 and Rs 21.69 in Q1CY25. CY25 Financial Highlights: Revenue from Operations: Rs 8,784 million. Total Income: Rs 8,968 million. Profit Before Tax: Rs 3,203 million (inclusive of an exceptional income of Rs 66 million). Net Profit for the Year: Rs 2,401 million. Total Comprehensive Income: Rs 2,387 million. Earnings Per Share (EPS): Rs 104.27. Business Highlights: Domestic and Export Performance: For Q1CY26, Domestic sales grew by 15.5% aided by product relaunch, and Export sales grew by 144.4% on a lower base compared to Q1CY25. Product Relaunches: Following a voluntary recall in 2024, the Company successfully relaunched Combiflam Suspension in June 2025 and Allegra Suspension and Depura Kids in September 2025. Exceptional Items: Exceptional items for CY25, pertain to a reversal of Rs 66 million related to demerger provisions made in CY24. Impact of New Labour Codes: The Company recognized an incremental financial impact of Rs 24 million as past service cost due to changes in the definition of wages under the new New Labour Codes notified in November 2025. Segment Reporting: The Company operates in a single business segment, namely 'Pharmaceutical Business'. Result PDF

• ट्रेंडलाईन
• 1 महिना 1 आठवड्यापूर्वी